...
首页> 外文期刊>Molecular pharmaceutics >Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation.
【24h】

Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation.

机译:通过原位siRNA - 白蛋白缀合,通过原位siRNA - 白蛋白缀合增强外渗,稳定性和体内心脏基因沉默。

获取原文
获取原文并翻译 | 示例
           

摘要

A potential barrier to progression of siRNA therapeutics to the clinic is the ability of these agents to cross the vascular endothelium to reach target cells. This study aimed to bypass the endothelial barrier by harnessing the extravasation capability of the serum protein albumin to allow siRNA to reach cardiomyocytes. A strategy for conjugating siRNA to albumin in vivo was developed that involved activating 3'-amine, 2'-O-methyl, phosphorothioate modified siRNA with succinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (SMCC) to yield maleimide-functionalized siRNA ("activated siRNA"); this thiol-reactive species can then irreversibly link to the single surface-exposed cysteine residue of endogenous albumin following intravenous administration. An IGF-I-receptor (IGF-IR) siRNA sequence which was effective in vitro was used to test the ability of the siRNA-albumin conjugate to bypass the endothelial barrier in Balb/C mice and produce silencing. In situ conjugation of maleimide-functionalized siRNA to albumin in mouse serum occurred within minutes of addition, and the resulting conjugate was found to be nuclease stable by SDS-PAGE analysis. In Sprague-Dawley rats, activated siRNA showed a significantly enhanced elimination half-life (75.9 +/- 18.2 min) compared to unactivated siRNA (5.1 +/- 0.2 min). Intravenous injection of this activated siRNA (1 mg/kg daily for four days) significantly reduced left ventricle IGF-IR mRNA to 64.1 +/- 4.1% of that in vehicle-treated animals (mean +/- SEM), while the control siRNA (unconjugated) had no effect (n = 4, P > 0.05). Imaging of microvessels from mice treated with fluorescein-labeled activated siRNA showed clear evidence of extravasation and cellular uptake in capillary endothelial cells, cardiomyocytes and vascular smooth muscle cells for mice treated with the activated siRNA but not mice treated with the unactivated siRNA. siRNA-albumin constructs are therefore capable of extravasation to the myocardium resulting in silencing in this otherwise silencing-resistant organ.
机译:对诊所的siRNA治疗剂的进展的潜在屏障是这些试剂通过血管内皮细胞到达靶细胞的能力。本研究旨在通过利用血清蛋白白蛋白的外渗能力来绕过内皮屏障,使siRNA达到心肌细胞。开发了一种在体内将siRNA与白蛋白缀合物的策略,其中涉及激活3'-胺,2'-O-甲基,硫代磷酸酯改性siRNA,用琥珀酰亚胺酰亚甲基环己烷-1-羧酸酯(SMCC),得到马来酰亚胺 - 官能化siRNA(“活化siRNA”);然后,这种硫醇反应性物质可以不可逆地链接到静脉内给药后内源白蛋白的单表面暴露的半胱氨酸残基。在体外有效的IGF-I受体(IGF-IR)siRNA序列用于测试siRNA-白蛋白缀合物绕过BALB / C小鼠中内皮屏障的能力并产生沉默。将马来酰亚胺官能化siRNA与白蛋白在小鼠血清中的原位缀合在加入的几分钟内发生,并且通过SDS-PAGE分析发现所得的缀合物是核酸酶的核酸酶。在Sprague-Dawley大鼠中,与未激活的siRNA(5.1 +/- 0.2分钟)相比,活化的siRNA显示出显着增强的消除半衰期(75.9 +/- 18.2分钟)。静脉注射该活化的siRNA(每天1mg / kg 4天)显着降低了左心室IGF-IR mRNA至64.1 +/- 4.1%,在载体处理的动物中(平均值+/-扫描),而对照siRNA (未舒适的)没有影响(n = 4,p> 0.05)。用荧光素标记的激活siRNA处理的小鼠的微血管成像显示出用活化的siRNA处理的小鼠的毛细血管内皮细胞,心肌细胞和血管平滑肌细胞的外渗和细胞摄取的明确证据表明,但没有用未致死的siRNA处理的小鼠。因此,siRNA-白蛋白构建体能够在这种抗菌器官中脱离心肌静置导致心肌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号